Bayer DCA 2000 Hemoglobin A1C Testing Analyzer

Accuracy, precision and reproducibility with the convenience of in-office results.
The DCA 2000®+ Analyzer is a point-of-care diabetes management platform that performs both hemoglobin A1c and microalbumin/creatinine tests in minutes. The DCA 2000®+ analyzer allows healthcare professionals to make immediate diabetes management adjustments. Quantitative measurement of HbA1c in blood allows effective preventive treatment to reduce the risk of retinopathy, nephropathy and neuropathy in patients with diabetes. The system also measures low concentrations of albumin, creatinine and albumin/creatinine ratio in urine. The method permits decentralized testing using random urine samples, enabling early detection of complications associated with renal disease.

• Totally self-contained reagent cartridges — no reagent preparation, mixing or handling
• Sample collection capillary holder is an integral part of unique reagent cartridge
• No costly, time-consuming calibration — factory-calibrated instrument eliminates all wet calibrations
• Screen displays all instructions, calibration status and testing information and results
• Up to 16 results stored in memory for convenient recordkeeping

• Review during patient visit, adjust blood glucose control regimen as appropriate
• Conforms with current guidelines for effective management

• Guide and reinforce your patients to maintain target blood glucose levels
• Quantitative HbA1c value in 6 minutes from capillary blood Low cost per test
• Monoclonal antibody method provides outstanding accuracy and precision
• Correlation study shows 99% agreement with the HPLC method
• Coefficients of variation <5% show excellent precision

• In IDDM (insulin-dependent diabetes mellitus) patients, intensive insulin treatment:
  • Delays the onset and slows the progression of microvascular complications
  • Produces significant financial savings when part of long-term monitoring and control
• One reagent cartridge provides results for both microalbumin and creatinine as well as an automatic calculation of the albumin-to-creatinine ratio
• Quantitative results and calculated ratio displayed within 7 minutes using random urine sample

• Maintaining average blood glucose levels (120 mg/dL; 6.7 mmol/L; HbA1c 6%) lowers risk of complications
• Three- to four-times-daily blood glucose monitoring is recommended
• Establish and follow a coherent approach of combined nutritional counseling, self-management training and possible hospitalization for therapy initiation

• HbA1c results monitor glucose control over the preceding 90 to 120 days
• Complete normalization of glycemia levels may prevent complications
• Quarterly HbA1c determination recommended for all insulin-treated patients
• Recommendation also includes test for microalbuminuria and others, as indicated

• Intensive diabetes management delays the onset of microalbuminuria -an early indicator of renal disease
• Microalbumin-to-creatinine ratio from a random urine sample is as valid an indicator of microalbuminuria as a timed 24-hour sampling
• Persistent microalbuminuria (30 to 300 mg/day) indicates the earliest stage of diabetic nephropathy
• May also signal presence of hypertension and the need to begin antihypertensive therapy
• Test for microalbuminuria should be performed yearly on postpubertal patients who have had diabetes for at least 5 years